Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Leukemia

A Phase 1, Open-Label, Dose-Finding Study Of Cc-90009, A Novel Cereblon E3 Ligase Modulating Drug, In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia

CC-90009 is a new investigational product (IP) that has a strong biological rationale for the treatment of subjects with AML. This Phase I study is designed to determine the safety and tolerability of CC-90009 as well as evaluating the biologic and clinical activity in subjects with relapsed or refractory AML.

Status: Accepting New Patients
Principal Investigator: Jessica Altman

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

This study in being done to determine what affects (good and bad) the therapy blinatumomab has on acute lymphoblastic leukemia (ALL).

Status: Accepting New Patients
Principal Investigator: Shira Dinner

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with Lymphomas Associated with Immunosuppression

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Phase Ib Study of Nivolumab and Dasatinib in Patients with Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

The purpose of this research study is to determine the MTD of nivolumab when given in combination with dasatinib in patients with relapsed/refractory Ph+ ALL.

Status: Accepting New Patients
Principal Investigator: Shira Dinner

A Phase 3, MultiCenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

To determine if an investigational agent known as AG-221 is safe and effective in treating Late Stage Acute Myeloid Leukemia, compared with those commonly used treatment options (also called conventional care regimens).

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

A Phase I, Open, Cohort Dose Escalation Trial with BI 836858 in Patients with Refractory or Relapsed Acute Myeloid Leukemia

The purpose of this research study is three-fold: to identify the maximum tolerated dose, that is, the highest dose of the study drug that does not cause unacceptable side effects; to obtain information on the safety and effectiveness in people given the study drug alone; and to measure and evaluate the behavior of the study drug in the blood.

Status: Accepting New Patients
Principal Investigator: Jessica Altman

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)

The main purpose of the study is to determine how safe and tolerable the study drug, Alisertib, is in patients with AMKL and in patients with MF.

Status: Accepting New Patients
Principal Investigator: Brady Stein

An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

This study is divided into 2 parts. The main purpose of the first part of this study (phase 1b) is to evaluate the side effects and risks of an investigational drug, TAK-659, to identify the highest dose that can be tolerated safely, and to decide upon the recommended dose for the second part of the study. The second part of this study (phase 2) will evaluate how well AML responds to the investigational drug.

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Wed - August 16, 2017 - 02:50 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.